08:07:55 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande



2025-02-21 Bokslutskommuniké 2024
2024-11-27 Kvartalsrapport 2024-Q3
2024-08-28 Kvartalsrapport 2024-Q2
2024-05-27 Årsstämma 2024
2024-05-17 Kvartalsrapport 2024-Q1
2024-05-15 X-dag ordinarie utdelning PRLD 0.00 SEK
2024-02-21 Bokslutskommuniké 2023
2023-11-27 Kvartalsrapport 2023-Q3
2023-11-27 Extra Bolagsstämma 2023
2023-08-29 Kvartalsrapport 2023-Q2
2023-05-12 X-dag ordinarie utdelning PRLD 0.00 SEK
2023-05-11 Årsstämma 2023
2023-05-11 Kvartalsrapport 2023-Q1
2023-02-21 Bokslutskommuniké 2022
2022-11-30 Kvartalsrapport 2022-Q3
2022-08-29 Kvartalsrapport 2022-Q2
2022-08-04 Extra Bolagsstämma 2022
2022-05-23 X-dag ordinarie utdelning PRLD 0.00 SEK
2022-05-20 Kvartalsrapport 2022-Q1
2022-05-20 Årsstämma 2022
2022-02-22 Bokslutskommuniké 2021
2021-11-23 Kvartalsrapport 2021-Q3
2021-08-31 Kvartalsrapport 2021-Q2
2021-05-06 X-dag ordinarie utdelning PRLD 0.00 SEK
2021-05-05 Kvartalsrapport 2021-Q1
2021-05-05 Årsstämma 2021
2021-02-24 Bokslutskommuniké 2020
2020-11-17 Kvartalsrapport 2020-Q3
2020-08-28 Kvartalsrapport 2020-Q2
2020-05-21 X-dag ordinarie utdelning PRLD 0.00 SEK
2020-05-20 Årsstämma 2020
2020-05-14 Kvartalsrapport 2020-Q1
2020-02-13 Bokslutskommuniké 2019
2019-11-20 Kvartalsrapport 2019-Q3
2019-08-28 Kvartalsrapport 2019-Q2
2019-05-16 Kvartalsrapport 2019-Q1
2019-05-16 Årsstämma 2019
2019-05-10 X-dag ordinarie utdelning PRLD 0.00 SEK
2018-11-20 Kvartalsrapport 2018-Q3
2018-08-28 Kvartalsrapport 2018-Q2
2018-05-17 X-dag ordinarie utdelning PRLD 0.00 SEK
2018-05-16 Årsstämma 2018
2018-05-16 Kvartalsrapport 2018-Q1
2018-02-14 Bokslutskommuniké 2017
2017-11-23 Kvartalsrapport 2017-Q3
2017-08-25 Kvartalsrapport 2017-Q2
2017-05-22 X-dag ordinarie utdelning PRLD 0.00 SEK
2017-05-19 Årsstämma 2017
2017-05-19 Kvartalsrapport 2017-Q1


ListaNordic SME Sweden
Prolight Diagnostics utvecklar testsystem inom POCT (Point of care testning). Testerna används utanför sjukhuslaboratorium för att möjliggöra snabba bedömningar av patienters hälsa. Bolagets POCT-Plattform är i utveckling med avsikt att mäta flera biomarkörer samtidigt. En viktig del i arbetet är således att korta ner tiden för provresultaten, särskilt viktigt för patienter med hjärtbesvär. Bolaget grundades år 1999 och har sitt huvudkontor i Lund.
2024-05-20 08:00:00

Prolight Diagnostics today announces the company will initiate a trial at Guy’s and St Thomas’NHS Foundation Trust and King’s College London to pre-validate assay and prototype performance of the Psyros POC system. The trial is supported by the recently awarded NIHR i4i PDA grant. Initial data with patient samples will be generated in Q3 2024 and results are expected in Q4 2024.
Clinical Advisory Board member, Professor Michael Marber, will be principal clinical investigator. The data generated from this trial with patient samples will be used for final optimization of the assay and the Psyros platform, to give high levels of confidence when entering the clinical validation study of the commercial POC system in 2025.
“The prestigious i4i PDA grant enables us to perform the pre validation study at highly respected St Thomas’ hospital in London. Hence, we will be even better prepared to secure the optimal outcome of the full clinical performance validation study next year,” said Ulf Bladin, CEO of Prolight Diagnostics.
“Stratification of patients at risk of heart attack relies on high-sensitivity troponin testing. Bringing these tests to the point-of-care allows faster decision making and earlier safe discharge of a large proportion of patients suspected of heart attack. We look forward greatly to collaborating on this project,” said Michael Marber, Consultant Cardiologist at Guy’s and St Thomas’ NHS Foundation Trust and adjunct Professor of Cardiology at King’s College London.
About the NIHR
The mission of the National Institute for Health and Care Research (NIHR) is to improve the health and wealth of the nation through research. This is done by:
• Funding high quality, timely research that benefits the NHS, public health and social care;
• Investing in world-class expertise, facilities and a skilled delivery workforce to translate discoveries into improved treatments and services;
• Partnering with patients, service users, carers and communities, improving the relevance, quality and impact of our research;
• Attracting, training and supporting the best researchers to tackle complex health and social care challenges;
• Collaborating with other public funders, charities and industry to help shape a cohesive and globally competitive research system;
• Funding applied global health research and training to meet the needs of the poorest people in low and middle income countries.

NIHR is funded by the Department of Health and Social Care. Its work in low and middle income countries is principally funded through UK international development funding from the UK government.